Published in Vaccine on August 13, 2010
Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother (2011) 0.87
Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen. Cancers (Basel) (2011) 0.78
Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma. Cancers (Basel) (2016) 0.75
Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. J Interferon Cytokine Res (2015) 0.75
The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol (2008) 1.93
Instillation of mitomycin C after transurethral resection of bladder cancer impairs wound healing: an animal model. Anticancer Res (2011) 1.50
Higher than expected association of clinical prostate and bladder cancers. J Urol (2008) 1.49
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
Finding unrecognized information in overactive bladder clinical trial data: a new approach to understanding placebo and treatment effects. Neurourol Urodyn (2012) 1.40
N-Acetyltransferases and the susceptibility to benzidine-induced bladder carcinogenesis. Int J Cancer (2007) 1.38
Antimuscarinic use among individuals with urinary incontinence who reside in long-term care facilities. Int Urol Nephrol (2013) 1.38
Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol (2008) 1.28
The spectrum of eosinophilic cystitis in males: case series and literature review. Arch Pathol Lab Med (2009) 1.24
Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg (2006) 1.23
Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer. BJU Int (2008) 1.04
Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Biochem Pharmacol (2005) 1.04
Shape Signatures: speeding up computer aided drug discovery. Drug Discov Today (2006) 1.03
Characterization of prostate cancer missed by sextant biopsy. Clin Prostate Cancer (2003) 1.03
The role of prevalence in the diagnosis of prostate cancer. Cancer Control (2006) 1.02
Epidemiology of prostate cancer in Africa: another step in the understanding of the disease? Curr Probl Cancer (2007) 1.01
Higher than expected association of clinical prostate and bladder cancers. J Urol (2005) 0.97
Saturation biopsies for prostate cancer: current uses and future prospects. Nat Rev Urol (2009) 0.95
A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol (2011) 0.94
IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro. J Immunother (2007) 0.93
Correlation of the genotypes for N-acetyltransferases 1 and 2 with double bladder and prostate cancers in a case-comparison study. Anticancer Res (2003) 0.91
Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Cancer (2004) 0.90
Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck (2011) 0.88
Association of prostate cancer and manganese superoxide dismutase AA genotype influenced by presence of occult cancer in control group. Urology (2008) 0.87
Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic. Cancer Immunol Immunother (2010) 0.87
Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother (2011) 0.87
Comparison of ante- and post-mortem PSA levels for epidemiological studies. Anticancer Res (2005) 0.86
Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2. Int Immunopharmacol (2003) 0.85
MnSOD genotype and prostate cancer risk as a function of NAT genotype and smoking status. In Vivo (2009) 0.85
Update on the diagnosis and management of prostate cancer. Can J Urol (2008) 0.85
Pathological characteristics of prostate cancer in elderly men. J Urol (2009) 0.83
Temporal trends and racial disparities in global prostate cancer prevalence. Can J Urol (2014) 0.83
Occult prostate cancer effects the results of case-control studies due to verification bias. Anticancer Res (2008) 0.82
T cell targeted immune enhancement yields effective T cell adjuvants. Int Immunopharmacol (2003) 0.82
Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection. Can J Urol (2006) 0.81
Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. Int J Cancer (2002) 0.79
A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. Cancer Immunol Immunother (2011) 0.79
Autopsy evaluation of a prostate cancer case treated with brachytherapy. Anticancer Res (2009) 0.78
The importance of research by urology residents: a thousand points of light. Can J Urol (2007) 0.78
Updating the prostate cancer risk indicator for contemporary biopsy schemes. Can J Urol (2011) 0.78
Differential gene expression in human prostate cancer cells adapted to growth in bone in Beige mice. Urol Oncol (2003) 0.77
Immunopharmacology of thymosin alpha1 and cytokine synergy. Ann N Y Acad Sci (2007) 0.77
High prevalence of bilateral varicoceles confirmed with ultrasonography. Int Urol Nephrol (2003) 0.76
Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector. Eur Urol (2002) 0.76
New developments in prostate cancer screening and prevention. Can J Urol (2009) 0.75
Editorial comment. Urology (2010) 0.75
Inspiring urology trainees to enter academic careers. Indian J Urol (2009) 0.75
Editorial comment. Urology (2011) 0.75
Combination of radiation and vaccination with autologous tumor cells expressing IL-2, IFN-gamma and GM-CSF for treatment of murine renal carcinoma. In Vivo (2003) 0.75
Editorial comment. J Urol (2012) 0.75
Benzotropolone inhibitors of estradiol methylation: kinetics and in silico modeling studies. Bioorg Med Chem (2005) 0.75
Is penile preservation of distal corporal invasive penile cancer sufficient treatment? J Urol (2013) 0.75
T cell immunostimulation by methyl inosine 5'-monophosphate: application to infectious diseases. Int Immunopharmacol (2003) 0.75
Perspectives on the epidemiology of prostate cancer. Can J Urol (2009) 0.75
Changing of the guard at the CJU. Can J Urol (2009) 0.75
Preclinical studies with IRX-2 and thymosin alpha1 in combination therapy. Ann N Y Acad Sci (2010) 0.75
Urology, the primary care physician, and health care reform. Can J Urol (2009) 0.75
Prostate cancer detection: beware of the low PSA. Can J Urol (2007) 0.75
Urologic cancer in Africa--papers from the African Organization for Research and Training in Cancer (AORTIC) meeting. Can J Urol (2008) 0.75
1500 gram suprarenal mass: a case report. Can J Urol (2007) 0.75
Protection by methyl inosine monophosphate (MIMP) against aerosol influenza virus infection in mice. Int Immunopharmacol (2002) 0.75
Legends and new techniques in urology: what great expectations are made of. Can J Urol (2008) 0.75
Invention, innovation, and evocation. Can J Urol (2008) 0.75
To circumcise or not to circumcise: the medical debate over a religious and cultural tradition. Can J Urol (2008) 0.75